Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure.
intestinal failure
parenteral nutrition
quality of life
short bowel syndrome
teduglutide
Journal
JPEN. Journal of parenteral and enteral nutrition
ISSN: 1941-2444
Titre abrégé: JPEN J Parenter Enteral Nutr
Pays: United States
ID NLM: 7804134
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
19
12
2018
revised:
22
02
2019
accepted:
13
03
2019
pubmed:
23
4
2019
medline:
20
2
2021
entrez:
23
4
2019
Statut:
ppublish
Résumé
Teduglutide reduces or eliminates parenteral support (PS) dependency in patients with short bowel syndrome (SBS). Recent post hoc analyses demonstrated that effects are correlated with baseline PS volume. We assessed the SBS-related quality-of-life (QoL) impact of teduglutide, particularly whether improvements are greater among subgroups achieving more PS volume reduction. Using phase 3 trial data of teduglutide in patients with SBS (NCT00798967), change in Short Bowel Syndrome-Quality of Life (SBS-QoL) scores from baseline were compared between teduglutide vs placebo in the overall population and subgroups classified by baseline PS volume requirement, disease etiology, and bowel anatomy. Generalized estimating equation models were fitted to assess impact of teduglutide on SBS-related QoL using data from all visits, adjusted for baseline characteristics. Of 86 patients, 43 each were randomized to teduglutide or placebo (mean age: 51 vs 50 years, respectively). In adjusted analyses, teduglutide had a nonsignificant reduction (improvement) of -8.6 points (95% CI: 2.6 to -19.8) in SBS-QoL sum score from baseline to Week-24 vs placebo. The impact of teduglutide varied by subgroup. Patients treated with teduglutide experienced significantly greater reductions in SBS-QoL sum score at Week-24 vs placebo in 2 subgroups, ie, the third (highest) tertile baseline PS volume (-27.3, 95% CI: -50.8 to -3.7) and inflammatory bowel disease (IBD; -29.6, 95% CI: -46.3 to -12.9). Results were similar for SBS-QoL subscale and item scores. The impact of teduglutide treatment on SBS-related QoL vs placebo varied among subgroups and was significant and most pronounced among patients with highest baseline PS volume requirement or IBD.
Sections du résumé
BACKGROUND
Teduglutide reduces or eliminates parenteral support (PS) dependency in patients with short bowel syndrome (SBS). Recent post hoc analyses demonstrated that effects are correlated with baseline PS volume. We assessed the SBS-related quality-of-life (QoL) impact of teduglutide, particularly whether improvements are greater among subgroups achieving more PS volume reduction.
METHODS
Using phase 3 trial data of teduglutide in patients with SBS (NCT00798967), change in Short Bowel Syndrome-Quality of Life (SBS-QoL) scores from baseline were compared between teduglutide vs placebo in the overall population and subgroups classified by baseline PS volume requirement, disease etiology, and bowel anatomy. Generalized estimating equation models were fitted to assess impact of teduglutide on SBS-related QoL using data from all visits, adjusted for baseline characteristics.
RESULTS
Of 86 patients, 43 each were randomized to teduglutide or placebo (mean age: 51 vs 50 years, respectively). In adjusted analyses, teduglutide had a nonsignificant reduction (improvement) of -8.6 points (95% CI: 2.6 to -19.8) in SBS-QoL sum score from baseline to Week-24 vs placebo. The impact of teduglutide varied by subgroup. Patients treated with teduglutide experienced significantly greater reductions in SBS-QoL sum score at Week-24 vs placebo in 2 subgroups, ie, the third (highest) tertile baseline PS volume (-27.3, 95% CI: -50.8 to -3.7) and inflammatory bowel disease (IBD; -29.6, 95% CI: -46.3 to -12.9). Results were similar for SBS-QoL subscale and item scores.
CONCLUSIONS
The impact of teduglutide treatment on SBS-related QoL vs placebo varied among subgroups and was significant and most pronounced among patients with highest baseline PS volume requirement or IBD.
Identifiants
pubmed: 31006876
doi: 10.1002/jpen.1588
pmc: PMC7004164
doi:
Substances chimiques
Gastrointestinal Agents
0
Peptides
0
teduglutide
7M19191IKG
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
119-128Informations de copyright
© 2019 The Authors. Journal of Parenteral and Enteral Nutrition published by Wiley Periodicals, Inc. on behalf of American Society for Parenteral and Enteral Nutrition.
Références
Clin Nutr. 2013 Feb;32(1):16-26
pubmed: 22959630
J Pediatr. 2001 Jul;139(1):27-33
pubmed: 11445790
Gastroenterology. 1997 Nov;113(5):1767-78
pubmed: 9352883
JPEN J Parenter Enteral Nutr. 2005 May-Jun;29(3):162-70
pubmed: 15837775
J Clin Gastroenterol. 2002 Mar;34(3):207-20
pubmed: 11873098
Clin Nutr. 2013 Oct;32(5):789-96
pubmed: 23274148
Pediatrics. 2005 May;115(5):1332-40
pubmed: 15867044
J Pediatr Surg. 2005 May;40(5):755-62
pubmed: 15937809
Expert Rev Pharmacoecon Outcomes Res. 2011 Apr;11(2):163-9
pubmed: 21476818
Clin Nutr. 2013 Oct;32(5):713-21
pubmed: 23587733
JPEN J Parenter Enteral Nutr. 2005 Sep-Oct;29(5):337-43; discussion 343-4
pubmed: 16107596
Scand J Gastroenterol. 2008;43(9):1057-65
pubmed: 18609190
J Pediatr. 2017 Feb;181:102-111.e5
pubmed: 27855998
Gut. 2006 Aug;55 Suppl 4:iv1-12
pubmed: 16837533
Clin Gastroenterol Hepatol. 2006 Jan;4(1):6-10
pubmed: 16431298
Clin Nutr. 2015 Apr;34(2):171-80
pubmed: 25311444
Gastroenterology. 2012 Dec;143(6):1473-1481.e3
pubmed: 22982184
Gut. 2011 Jul;60(7):902-14
pubmed: 21317170
Gastroenterology. 2018 Mar;154(4):874-885
pubmed: 29174926
Therap Adv Gastroenterol. 2012 May;5(3):159-71
pubmed: 22570676
JPEN J Parenter Enteral Nutr. 2014 May;38(4):427-37
pubmed: 24247092
J Pediatr. 2004 Aug;145(2):157-63
pubmed: 15289760
Clin Nutr. 2016 Apr;35(2):247-307
pubmed: 26944585
Am J Gastroenterol. 2004 Jul;99(7):1386-95
pubmed: 15233682